Identification	O
of	O
APC2	O
,	O
a	O
homologue	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
tumour	I-Disease
suppressor	O
.	O

In	O
colon	B-Disease
carcinoma	I-Disease
cells	O
,	O
loss	O
of	O
APC	O
leads	O
to	O
the	O
accumulation	O
of	O
betacatenin	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
Tcf	O
-	O
4	O
transcription	O
factor	O
(	O
reviewed	O
in	O
[	O
1	O
]	O
[	O
2	O
]	O
)	O
.	O

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	B-Disease
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O

Although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	B-Disease
cancer	I-Disease
families	O
analysed	O
from	O
eastern	O
England	O
,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
English	O
HNPCC	B-Disease
kindreds	O
analysed	O
.	O

In	O
contrast	O
,	O
the	O
MSH2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	O
colorectal	B-Disease
families	O
from	O
Newfoundland	O
.	O

These	O
findings	O
suggested	O
a	O
founder	O
effect	O
within	O
Newfoundland	O
similar	O
to	O
that	O
reported	O
by	O
others	O
for	O
two	O
MLH1	O
mutations	O
in	O
Finnish	O
HNPCC	B-Disease
families	O
.	O

The	O
risk	O
of	O
colorectal	B-Disease
cancer	I-Disease
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
males	O
than	O
females	O
(	O
0	O
.	O
63	O
v	O
0	O
.	O
30	O
and	O
0	O
.	O
84	O
v	O
0	O
.	O
44	O
at	O
ages	O
50	O
and	O
60	O
years	O
,	O
respectively	O
)	O
.	O

For	O
females	O
there	O
was	O
a	O
high	O
risk	O
of	O
endometrial	B-Disease
cancer	I-Disease
(	O
0	O
.	O
5	O
at	O
age	O
60	O
years	O
)	O
and	O
premenopausal	B-Disease
ovarian	I-Disease
cancer	I-Disease
(	O
0	O
.	O
2	O
at	O
50	O
years	O
)	O
.	O

Age	O
of	O
onset	O
(	O
AO	O
)	O
of	O
Huntington	B-Disease
disease	I-Disease
(	O
HD	B-Disease
)	O
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	B-Disease
gene	O
.	O

We	O
therefore	O
determined	O
APOE	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
in	O
the	O
HD	B-Disease
gene	O
for	O
138	O
HD	B-Disease
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
CAG	O
repeat	O
length	O
.	O

In	O
addition	O
to	O
highlighting	O
the	O
effect	O
of	O
the	O
normal	O
repeat	O
length	O
upon	O
AO	O
in	O
maternally	O
inherited	O
HD	B-Disease
and	O
in	O
male	O
patients	O
,	O
we	O
show	O
that	O
the	O
APOE	O
epsilon2epsilon3	O
genotype	O
is	O
associated	O
with	O
significantly	O
earlier	O
AO	O
in	O
males	O
than	O
in	O
females	O
.	O

The	O
serum	O
of	O
a	O
29	O
-	O
year	O
old	O
woman	O
with	O
a	O
recent	O
episode	O
of	O
disseminated	B-Disease
gonococcal	I-Disease
infection	I-Disease
and	O
a	O
history	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
was	O
found	O
to	O
lack	O
serum	O
hemolytic	O
complement	O
activity	O
.	O

Complete	B-Disease
absence	I-Disease
of	I-Disease
C7	I-Disease
was	O
also	O
found	O
in	O
one	O
sibling	O
who	O
had	O
the	O
clinical	O
syndrome	O
of	O
meningococcal	B-Disease
meningitis	I-Disease
and	O
arthritis	B-Disease
as	O
a	O
child	O
and	O
in	O
this	O
siblings	O
clinically	O
well	O
eight	O
-	O
year	O
-	O
old	O
son	O
.	O

This	O
report	O
represents	O
the	O
first	O
cases	O
of	O
C7	B-Disease
deficiency	I-Disease
associated	O
with	O
infectious	O
complications	O
and	O
suggests	O
that	O
bactericidal	O
activity	O
may	O
be	O
important	O
in	O
host	O
defense	O
against	O
bacteremic	B-Disease
neisseria	I-Disease
infections	I-Disease
.	O

Increased	O
incidence	O
of	O
cancer	B-Disease
in	O
patients	O
with	O
cartilage	B-Disease
-	I-Disease
hair	I-Disease
hypoplasia	I-Disease
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
further	O
evaluate	O
this	O
risk	O
among	O
patients	O
with	O
CHH	B-Disease
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

RESULTS	O
A	O
statistically	O
significant	O
excess	O
risk	O
of	O
cancer	B-Disease
was	O
seen	O
among	O
the	O
patients	O
with	O
CHH	B-Disease
(	O
standardized	O
incidence	O
ratio	O
6	O
.	O
9	O
,	O
95	O
%	O
confidence	O
interval	O
2	O
.	O
3	O
to	O
16	O
)	O
,	O
which	O
was	O
mainly	O
attributable	O
to	O
non	B-Disease
-	I-Disease
Hodgkins	I-Disease
lymphoma	I-Disease
(	O
standardized	O
incidence	O
ratio	O
90	O
,	O
95	O
%	O
confidence	O
interval	O
18	O
to	O
264	O
)	O
.	O

The	O
cancer	B-Disease
incidence	O
among	O
the	O
siblings	O
or	O
the	O
parents	O
did	O
not	O
differ	O
from	O
the	O
average	O
cancer	B-Disease
incidence	O
in	O
the	O
Finnish	O
population	O
.	O

Genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
.	O

In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
DPD	B-Disease
deficiency	I-Disease
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	B-Disease
of	I-Disease
DPD	I-Disease
.	O

A	O
large	O
phenotypic	O
variability	O
has	O
been	O
observed	O
,	O
with	O
convulsive	B-Disease
disorders	I-Disease
,	O
motor	B-Disease
retardation	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
being	O
the	O
most	O
abundant	O
manifestations	O
.	O

An	O
altered	O
beta	O
-	O
alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	B-Disease
abnormalities	I-Disease
encountered	O
in	O
patients	O
with	O
DPD	B-Disease
deficiency	I-Disease
.	O

Borjeson	B-Disease
-	I-Disease
Forssman	I-Disease
-	I-Disease
Lehmann	I-Disease
syndrome	I-Disease
(	O
BFLS	B-Disease
)	O
is	O
a	O
syndromal	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
,	O
which	O
maps	O
by	O
linkage	O
to	O
the	O
q26	O
region	O
of	O
the	O
human	O
X	O
chromosome	O
.	O

Germline	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
mutations	O
predispose	O
to	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
and	O
colorectal	B-Disease
cancer	I-Disease
.	O

Inherited	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
were	O
described	O
recently	O
in	O
three	O
Maori	O
kindreds	O
with	O
familial	B-Disease
gastric	I-Disease
cancer	I-Disease
.	O

Each	O
family	O
contained	O
(	O
i	O
)	O
two	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years	O
;	O
or	O
(	O
ii	O
)	O
three	O
or	O
more	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
.	O

In	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non	O
-	O
penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	B-Disease
and	I-Disease
colorectal	I-Disease
cancer	I-Disease
;	O
thus	O
,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	B-Disease
cancer	I-Disease
,	O
a	O
CDH1	O
mutation	O
carrier	O
developed	O
colorectal	B-Disease
cancer	I-Disease
at	O
age	O
30	O
years	O
.	O

However	O
,	O
only	O
a	O
minority	O
of	O
familial	O
gastric	B-Disease
cancers	I-Disease
can	O
be	O
accounted	O
for	O
by	O
CDH1	O
mutations	O
.	O

A	O
zinc	O
finger	O
truncation	O
of	O
murine	O
WT1	O
results	O
in	O
the	O
characteristic	O
urogenital	B-Disease
abnormalities	I-Disease
of	O
Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
.	O

The	O
Wilms	B-Disease
tumor	I-Disease
-	O
suppressor	O
gene	O
,	O
WT1	O
,	O
plays	O
a	O
key	O
role	O
in	O
urogenital	O
development	O
,	O
and	O
WT1	B-Disease
dysfunction	I-Disease
is	O
implicated	O
in	O
both	O
neoplastic	B-Disease
(	O
Wilms	B-Disease
tumor	I-Disease
,	O
mesothelioma	B-Disease
,	O
leukemias	B-Disease
,	O
and	O
breast	B-Disease
cancer	I-Disease
)	O
and	O
nonneoplastic	B-Disease
(	O
glomerulosclerosis	B-Disease
)	O
disease	O
.	O

DDS	B-Disease
patients	O
are	O
constitutionally	O
heterozygous	O
for	O
exonic	O
point	O
mutations	O
in	O
WT1	O
,	O
which	O
include	O
mutations	O
predicted	O
to	O
truncate	O
the	O
protein	O
within	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
(	O
ZF	O
)	O
region	O
.	O

We	O
report	O
that	O
heterozygosity	O
for	O
a	O
targeted	O
murine	O
Wt1	O
allele	O
,	O
Wt1	O
(	O
tmT396	O
)	O
,	O
which	O
truncates	O
ZF3	O
at	O
codon	O
396	O
,	O
induces	O
mesangial	B-Disease
sclerosis	I-Disease
characteristic	O
of	O
DDS	B-Disease
in	O
adult	O
heterozygous	O
and	O
chimeric	O
mice	O
.	O

Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B-Disease
hemochromatosis	I-Disease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1	O
.	O

Hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption	O
.	O

Neurophysiologic	O
follow	O
-	O
up	O
of	O
long	O
-	O
term	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
.	O

OBJECTIVE	O
To	O
monitor	O
the	O
effects	O
of	O
dietary	O
treatment	O
in	O
adult	O
-	O
onset	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
by	O
means	O
of	O
somatosensory	O
evoked	O
potentials	O
(	O
SEPs	O
)	O
and	O
motor	O
evoked	O
potentials	O
(	O
MEPs	O
)	O
.	O

METHODS	O
Eight	O
patients	O
with	O
adult	O
-	O
onset	O
ALD	B-Disease
underwent	O
clinical	O
examination	O
,	O
brain	O
and	O
spine	O
MRI	O
,	O
and	O
SEP	O
and	O
MEP	O
studies	O
before	O
and	O
after	O
3	O
years	O
of	O
Lorenzos	O
oil	O
dietary	O
therapy	O
.	O

After	O
treatment	O
,	O
the	O
three	O
patients	O
with	O
pure	O
spinal	B-Disease
abnormalities	I-Disease
showed	O
clinical	O
and	O
neurophysiologic	O
worsening	O
,	O
whereas	O
the	O
two	O
patients	O
with	O
a	O
more	O
advanced	O
stage	O
of	O
disease	O
(	O
exhibited	O
by	O
SEPs	O
)	O
showed	O
substantially	O
unchanged	O
clinical	O
and	O
neurophysiologic	O
features	O
.	O

GCH1	O
mutation	O
in	O
a	O
patient	O
with	O
adult	O
-	O
onset	O
oromandibular	B-Disease
dystonia	I-Disease
.	O

These	O
findings	O
demonstrate	O
that	O
GCH1	O
mutations	O
must	O
be	O
considered	O
even	O
in	O
patients	O
with	O
dystonic	B-Disease
symptoms	O
not	O
typical	O
of	O
dopa	B-Disease
-	I-Disease
responsive	I-Disease
dystonia	I-Disease
.	O

We	O
extensively	O
analyzed	O
genomic	O
DNA	O
and	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
from	O
62	O
unrelated	O
Korean	O
patients	O
with	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
FAP	B-Disease
)	O
for	O
identification	O
of	O
germline	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
APC	B-Disease
)	O
gene	O
mutations	O
.	O

Our	O
results	O
confirm	O
that	O
the	O
mutation	O
detection	O
rate	O
with	O
PTT	O
was	O
superior	O
to	O
that	O
with	O
SSCP	O
,	O
and	O
suggest	O
that	O
PTT	O
would	O
be	O
a	O
more	O
practical	O
screening	O
method	O
to	O
detect	O
germline	O
mutations	O
of	O
the	O
APC	B-Disease
gene	O
in	O
FAP	B-Disease
patients	O
.	O

Deficiency	B-Disease
of	I-Disease
the	I-Disease
ninth	I-Disease
component	I-Disease
of	I-Disease
human	I-Disease
complement	I-Disease
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-Disease
deficiency	I-Disease
in	O
Japan	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries	O
.	O

Genetic	O
analyses	O
of	O
Japanese	O
C9	B-Disease
deficiency	I-Disease
have	O
shown	O
that	O
a	O
C	O
-	O
to	O
-	O
T	O
transition	O
leading	O
to	O
TGA	O
stop	O
codon	O
for	O
Arg95	O
in	O
exon	O
4	O
of	O
the	O
C9	O
gene	O
(	O
Arg95Stop	O
)	O
is	O
common	O
in	O
Japanese	O
C9	B-Disease
deficiency	I-Disease
.	O

HFE	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
hereditary	B-Disease
hemochromatosis	I-Disease
(	O
Feder	O
,	O
J	O
.	O

Mutation	O
and	O
haplotype	O
studies	O
of	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
reveal	O
new	O
ancestral	O
relationships	O
and	O
evidence	O
for	O
a	O
high	O
carrier	O
frequency	O
with	O
reduced	O
penetrance	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	B-Disease
)	O
is	O
a	O
recessive	B-Disease
disorder	I-Disease
characterized	O
by	O
episodes	O
of	O
fever	O
with	O
serositis	B-Disease
or	O
synovitis	B-Disease
.	O

Consistent	O
with	O
another	O
recent	O
report	O
,	O
the	O
E148Q	O
mutation	O
was	O
observed	O
in	O
patients	O
of	O
several	O
ethnicities	O
and	O
on	O
multiple	O
microsatellite	O
haplotypes	O
,	O
but	O
haplotype	O
data	O
indicate	O
an	O
ancestral	O
relationships	O
between	O
non	O
-	O
Jewish	O
Italian	O
and	O
Ashkenazi	O
Jewish	O
patients	O
with	O
FMF	B-Disease
and	O
other	O
affected	O
populations	O
.	O

Autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
ALPS	B-Disease
)	O
is	O
a	O
disorder	B-Disease
of	I-Disease
lymphocyte	I-Disease
homeostasis	I-Disease
and	I-Disease
immunological	I-Disease
tolerance	I-Disease
.	O

Two	O
missense	O
Fas	O
variants	O
,	O
not	O
restricted	O
to	O
patients	O
with	O
ALPS	B-Disease
,	O
were	O
identified	O
.	O

Among	O
the	O
ALPS	B-Disease
-	O
associated	O
Fas	O
mutants	O
,	O
dominant	O
inhibition	O
of	O
apoptosis	O
was	O
much	O
more	O
pronounced	O
in	O
mutants	O
affecting	O
the	O
intracellular	O
,	O
versus	O
extracellular	O
,	O
portion	O
of	O
the	O
Fas	O
receptor	O
.	O

Significant	O
ALPS	B-Disease
-	O
related	O
morbidity	O
occurred	O
in	O
44	O
%	O
of	O
relatives	O
with	O
intracellular	O
mutations	O
,	O
versus	O
0	O
%	O
of	O
relatives	O
with	O
extracellular	O
mutations	O
.	O

Genetic	B-Disease
hemochromatosis	I-Disease
(	O
GH	B-Disease
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry	O
.	O

In	O
a	O
proportion	O
of	O
GH	B-Disease
patients	O
,	O
two	O
mutations	O
are	O
present	O
,	O
C282Y	O
and	O
H63D	O
.	O

These	O
selection	O
pressures	O
could	O
be	O
due	O
to	O
infectious	B-Disease
diseases	I-Disease
,	O
environmental	O
conditions	O
,	O
or	O
other	O
genetic	B-Disease
disorders	I-Disease
such	O
as	O
anemia	B-Disease
.	O

Alkaptonuria	B-Disease
(	O
aku	B-Disease
)	O
,	O
an	O
inborn	B-Disease
error	I-Disease
of	I-Disease
metabolism	I-Disease
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O

Enlarged	B-Disease
vestibular	I-Disease
aqueduct	I-Disease
(	O
EVA	B-Disease
)	O
,	O
known	O
as	O
the	O
most	O
common	O
form	O
of	O
inner	B-Disease
ear	I-Disease
abnormality	I-Disease
,	O
has	O
recently	O
been	O
of	O
particular	O
genetic	O
interest	O
because	O
this	O
anomaly	O
is	O
inherited	O
in	O
a	O
recessive	O
manner	O
.	O

In	O
the	O
present	O
study	O
,	O
seven	O
mutations	O
in	O
the	O
PDS	B-Disease
gene	O
(	O
PDS	O
)	O
,	O
the	O
gene	O
responsible	O
for	O
Pendred	B-Disease
syndrome	I-Disease
,	O
have	O
been	O
found	O
in	O
families	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
sensorineural	I-Disease
hearing	I-Disease
loss	I-Disease
with	O
EVA	B-Disease
.	O

The	O
present	O
results	O
provide	O
evidence	O
that	O
mutations	O
in	O
PDS	O
cause	O
both	O
syndromic	B-Disease
and	I-Disease
non	I-Disease
-	I-Disease
syndromic	I-Disease
hearing	I-Disease
loss	I-Disease
.	O
.	O

The	O
classic	O
form	O
of	O
ALD	B-Disease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
)	O
,	O
with	O
rapid	O
neurologic	B-Disease
deterioration	I-Disease
leading	O
to	O
a	O
vegetative	O
state	O
.	O

Adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	B-Disease
dysfunction	I-Disease
.	O

METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B-Disease
cerebral	I-Disease
ALD	I-Disease
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B-Disease
ALD	I-Disease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B-Disease
.	O

We	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
ALD	B-Disease
by	O
genomic	O
Southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
RNA	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts	O
,	O
lymphoblastoid	O
cells	O
,	O
or	O
peripheral	O
blood	O
leukocytes	O
.	O

CONCLUSIONS	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	B-Disease
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	B-Disease
.	O
.	O

A	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta	O
-	O
catenin	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta	O
-	O
catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-Disease
tumours	I-Disease
resembling	O
pilomatricomas	B-Disease
.	O

Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-Disease
tumour	I-Disease
.	O

At	O
least	O
75	O
%	O
of	O
these	O
tumours	B-Disease
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

The	O
Pendred	B-Disease
syndrome	I-Disease
gene	O
encodes	O
a	O
chloride	O
-	O
iodide	O
transport	O
protein	O
.	O

Pendred	B-Disease
syndrome	I-Disease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-Disease
deafness	I-Disease
and	O
characterized	O
by	O
congenital	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
and	O
goitre	B-Disease
.	O

Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B-Disease
syndrome	I-Disease
.	O
.	O

Hereditary	B-Disease
hemochromatosis	I-Disease
(	O
HH	B-Disease
)	O
is	O
a	O
common	O
autosomal	B-Disease
recessive	I-Disease
genetic	I-Disease
disorder	I-Disease
of	O
iron	O
metabolism	O
.	O

Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B-Disease
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non	O
-	O
C282Y	O
HH	B-Disease
chromosomes	O
.	O

The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	B-Disease
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
HH	B-Disease
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation	O
.	O

This	O
enrichment	O
of	O
S65C	O
among	O
HH	B-Disease
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	B-Disease
.	O

To	O
achieve	O
this	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
consecutive	O
ovarian	B-Disease
cancer	I-Disease
cases	O
.	O

This	O
is	O
the	O
first	O
population	O
-	O
based	O
ovarian	B-Disease
cancer	I-Disease
study	O
reporting	O
BRCA1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region	O
.	O

Several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	B-Disease
.	O

The	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
Caucasian	O
cancer	B-Disease
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele	O
-	O
specific	O
amplification	O
.	O

Adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-Disease
protein	I-Disease
deficiency	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
:	O
implications	O
for	O
therapy	O
.	O

Inherited	B-Disease
defects	I-Disease
in	O
the	O
peroxisomal	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
adrenoleukodystrophy	B-Disease
protein	O
(	O
ALDP	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B-Disease
disorder	I-Disease
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
X	B-Disease
-	I-Disease
ALD	I-Disease
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	B-Disease
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
.	O

However	O
,	O
a	O
defective	O
G2	O
-	O
M	O
checkpoint	O
in	O
these	O
cells	O
is	O
accompanied	O
by	O
extensive	O
chromosomal	B-Disease
abnormalities	I-Disease
.	O

Defective	O
CD95	O
/	O
APO	O
-	O
1	O
/	O
Fas	O
signal	O
complex	O
formation	O
in	O
the	O
human	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
,	I-Disease
type	I-Disease
Ia	I-Disease
.	O

Despite	O
heterozygosity	O
for	O
the	O
abnormal	O
allele	O
,	O
lymphocytes	O
from	O
ALPS	B-Disease
patients	O
showed	O
markedly	O
decreased	O
FADD	O
association	O
and	O
a	O
loss	O
of	O
caspase	O
recruitment	O
and	O
activation	O
after	O
CD95	O
crosslinking	O
.	O

These	O
data	O
suggest	O
that	O
intracytoplasmic	O
CD95	O
mutations	O
in	O
ALPS	B-Disease
impair	O
apoptosis	O
chiefly	O
by	O
disrupting	O
death	O
-	O
domain	O
interactions	O
with	O
the	O
signaling	O
protein	O
FADD	O
/	O
MORT1	O
.	O
.	O

Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	B-Disease
pedigrees	O
.	O

These	O
analyses	O
identified	O
two	O
novel	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
INV4	O
+	O
31A	O
-	O
-	O
>	O
G	O
and	O
INV11	O
+	O
18A	O
-	O
-	O
>	O
G	O
)	O
and	O
six	O
novel	O
AKU	B-Disease
mutations	O
(	O
INV1	O
-	O
1G	O
-	O
-	O
>	O
A	O
,	O
W60G	O
,	O
Y62C	O
,	O
A122D	O
,	O
P230T	O
,	O
and	O
D291E	O
)	O
,	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	O
found	O
in	O
AKU	B-Disease
.	O

Clinically	O
,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	B-Disease
,	O
severe	B-Disease
acroparesthesia	I-Disease
,	O
renal	B-Disease
failure	I-Disease
,	O
and	O
vasculopathy	B-Disease
of	I-Disease
the	I-Disease
heart	I-Disease
and	I-Disease
brain	I-Disease
.	O

By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence	O
-	O
based	O
detection	O
systems	O
,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha	B-Disease
-	I-Disease
Gal	I-Disease
A	I-Disease
deficiency	I-Disease
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
FD	B-Disease
.	O

Prenatal	O
diagnosis	O
by	O
FISH	O
in	O
a	O
family	O
with	O
Pelizaeus	B-Disease
-	I-Disease
Merzbacher	I-Disease
disease	I-Disease
caused	O
by	O
duplication	O
of	O
PLP	O
gene	O
.	O

Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
.	O

Patients	O
with	O
familial	B-Disease
APC	I-Disease
(	O
FAP	B-Disease
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B-Disease
gene	O
and	O
develop	O
multiple	O
colorectal	B-Disease
adenomas	I-Disease
and	O
subsequent	O
carcinomas	B-Disease
early	O
in	O
life	O
.	O

The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	B-Disease
mutation	O
(	O
genotype	O
-	O
phenotype	O
correlation	O
)	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B-Disease
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B-Disease
.	O

Wild	O
-	O
type	O
APC	B-Disease
activity	O
in	O
beta	O
-	O
catenin	O
-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B-Disease
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O

Germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
tumor	O
-	O
suppressor	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O

By	O
routine	O
screening	O
of	O
sera	O
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub	B-Disease
-	I-Disease
total	I-Disease
deficiency	I-Disease
of	I-Disease
C6	I-Disease
and	I-Disease
C7	I-Disease
.	O

Changes	O
at	O
P183	O
of	O
emerin	O
weaken	O
its	O
protein	O
-	O
protein	O
interactions	O
resulting	O
in	O
X	B-Disease
-	I-Disease
linked	I-Disease
Emery	I-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

Mutations	O
spanning	O
the	O
emerin	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
EDMD	B-Disease
.	O

